ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In the subpopulation of 43 reports with no CML, abortion rates were similar in the BCR::ABL1 TKI‐exposed group compared to other anticancers (ROR = 1.1 [0.38–3.0]) (FigureS9).